Drug intelligence / Profile preview

ASP0892

Development stage
Discontinued
Lead developer
Astellas Pharma
Modality
Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intramuscular
01

Overview

ASP0892 is a plasmid-based DNA vaccine developed for the mitigation of severe hypersensitivity reactions due to peanut allergy. It utilizes the LAMP-Vax platform and encodes lysosomal-associated membrane protein (LAMP) fused with major peanut allergens (Ara h 1, 2, and 3). The mechanism of action involves stimulation of Th1 immune responses to promote allergen-specific immune tolerance. ASP0892 was evaluated in phase 1 clinical trials in adults and adolescents with peanut allergy; it was well tolerated but did not show clinically meaningful improvements in food challenge outcomes. Development was discontinued after phase 1 due to lack of efficacy[1][2][5][6].

Other names
peanut allergy vaccine - immunomic
02

Targets

Ara h 2LAMP1 (Lysosomal-associated membrane protein 1)

Beyond the preview

Go deeper on ASP0892.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASP0892.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call